CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 2, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 19,000 shares of...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jan. 24, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced data from the Phase 1...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jan. 4, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 23,000 shares of...